According to a recent LinkedIn post from Beacon Therapeutics, data from its DAWN Phase 2 trial of investigational gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP) is scheduled to be presented at the 49th Macula Society Annual Meeting in San Diego. The presentation, led by Szilárd Kiss, MD, FACS, Professor of Ophthalmology and Genetic Medicine, will cover 9+ month safety, efficacy and surgical technique outcomes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Beacon Therapeutics is positioning laru-zova as a key asset in its gene therapy portfolio targeting severe ocular diseases. For investors, inclusion at a high-profile specialist meeting may indicate growing clinical and academic interest, and the nature of the data shared could influence perceptions of the program’s de-risking, potential partnering opportunities and the company’s longer-term value in rare retinal disease gene therapies.